OncoNano Medicine reports $10.05 million raised in equity offering

OncoNano Medicine, Inc. filed a Form D with the Securities and Exchange Commission dated October 1, 2026, disclosing an exempt securities offering. The filing lists the date of first sale as September 23, 2026, and is marked as a new notice rather than an amendment.¹

The company set a total offering amount of $15,000,000, with $10,051,615 already sold and $4,948,385 remaining to be sold.¹ Fourteen investors had put money into the offering as of the filing date.¹ The securities offered are classified as equity.¹

The offering is being made under the Rule 506(b) exemption.¹ Salem Partners LLC, based in Los Angeles, California, is listed as a sales compensation recipient, with solicitation occurring in California, Ohio, and Texas.¹ Sales commissions tied to the offering came to an estimated $402,065, with no finder's fees reported.¹ The filing states that the broker received that commission in cash and is also entitled to an additional 4.0% cash fee on any future sales, plus a warrant covering shares equal to 4% of the total shares sold in the transaction.

OncoNano Medicine is headquartered at 3060 Pegasus Park Drive in Dallas, Texas.¹ The related persons named in the filing include Brent Sorrells and Brett Giroir as executive officers, with Giroir also serving as a director, alongside directors John Dyett, Gina Jones, and Yumin Qui.¹ Brett P. Giroir, identified as Interim CEO/Chairman, signed the filing on October 1, 2026.¹